New pill tested for leukemia that Won't quit
NCT ID NCT05744739
Summary
This is an early, small study to find a safe and active dose of a new oral drug called tomivosertib for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. Up to 15 participants will take the pill daily in 28-day cycles while doctors closely monitor side effects and look for signs the drug is working against the cancer. The main goal is to determine the best dose to use in future studies that will combine tomivosertib with other leukemia drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.